Dr. Shan Lu’s laboratory working with the Infectious Disease Research Institute (IDRI) completed another test as part of the stability program for its GLA-SE adjuvant manufactured in 2016. The results show the adjuvant is very stable and can be used in more clinical trials.
PDPHV vaccine candidate was developed in the laboratory of Dr. Shan Lu at the University of Massachusetts Medical School (UMMS). In 2015, using the funding provided by NIAID’s IPCAVD program, IDRI manufactured the adjuvant specifically for PDPHV vaccine as part of the HVTN 124 clinical trial. At the time, a 4-year program was launched to monitor the stability of GLA-SE to support its continued use in the clinical trial. With the pending completion of HVTN124, the 48-month time point stability data review showed no noticeable degradation of the product.
WHV will use the remaining GLA-SE in more WHV planned clinical studies. Accordingly, WHV will work with IDRI to extend the stability study to further monitor the preservation of this adjuvant.
